The role of the neoadjuvant approach in the treatment of primary operable HER2-positive breast cancer

Neoadjuvant systemic therapy is an essential component of the comprehensive treatment of primary operable HER2-positive breast cancer. Therefore, it is extremely important to search for treatment efficacy predictors and optimal system for assessing tumor response to treatment. The study analyzed factors predicting pathological complete response (pCR) in patients with luminal and non-luminal HER2-positive tumor subtypes. The morphological assessment of the tumor response to treatment was carried out using the RCB system; additional characteristics of the residual tumor were studied as well. It was shown that a comprehensive assessment involving the use of the RCB system and determination of the Ki - 67 level helps to divide patients into prognostic groups and individualize the adjuvant therapy plan.